Skip to main
AUTL

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics (AUTL) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Autolus Therapeutics is positioned as a leader in developing next-generation programmed T-cell therapies for the treatment of cancer, specifically B-ALL. The company's clinical-stage pipeline, including Obe-cel, AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, and AUTO8, has promising potential for commercial use and could attract investor interest. Though Aucatzyl's potential in treating autoimmune diseases is a positive sign, the limited research in this area makes it a riskier option compared to its established use for B-ALL.

Bears say

Autolus Therapeutics is in a crowded market, with several other companies also developing CD19 CAR-T therapies for the treatment of cancer. Additionally, there is uncertainty with the company's pipeline, as their Phase 1 BOBCAT trial for Obe-cel in progressive MS is not expected to have initial data until 2026 and there may be challenges in commercializing their therapies due to high costs and production limitations. While the company has had some success with Aucatzyl, there is no guarantee that they will be able to replicate this success with their other therapies, and the potential for reduced market potential and regulatory setbacks could significantly impact their financial performance.

Autolus Therapeutics (AUTL) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Autolus Therapeutics (AUTL) Forecast

Analysts have given Autolus Therapeutics (AUTL) a Buy based on their latest research and market trends.

According to 4 analysts, Autolus Therapeutics (AUTL) has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Autolus Therapeutics (AUTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.